Loading...

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes

Print Friendly, PDF & Email

DIABETES 1 RELATED: HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study ( NCT03335371 ) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newly reported data provide additional […]